Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical...

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Ocrelizumab is a B-cell depleting therapy used for multiple sclerosis (MS).
• Scientific literature highlights an increased risk of infection associated with ocrelizumab treatment in patients with MS (PwMS).
• Iranian physicians require guidance for managing these infection risks.

Purpose of the Study:

• To develop evidence-based recommendations for screening and managing infections in PwMS initiating ocrelizumab therapy.
• To assist Iranian healthcare professionals in clinical decision-making regarding ocrelizumab-associated infection risks.

Main Methods:

• A modified Delphi consensus process was employed.
• A multidisciplinary expert panel (MS specialists, infectious disease specialists, gastrointestinal specialists) participated.
• Recommendations were developed based on scientific literature and clinical relevance.

Main Results:

• The expert panel formulated 67 consensus statements.
• Recommendations cover screening, prophylaxis, monitoring, and early treatment of infections.
• Specific infections addressed include tuberculosis, VZV, HBV, HCV, HIV, and secondary hypogammaglobulinemia.

Conclusions:

• The consensus provides a comprehensive framework for managing ocrelizumab-related infection risks in PwMS.
• These recommendations aim to optimize patient safety and treatment outcomes.
• The guidelines support informed decision-making for Iranian physicians regarding ocrelizumab therapy.